Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at ...
Editas Medicine EDIT reported new positive data from the phase I/II/III RUBY study of its lead candidate, reni-cel, in 18 patients with sickle cell disease (SCD) and the phase I/II EdiTHAL study of ...
Editas Medicine EDIT announced positive preliminary safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY study and the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback